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Abstract
Background: Escitalopram is licensed for use at doses up to 20 mg but is used clinically at higher doses. There is
limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD).
Methods: This open-label, pilot study was designed to investigate the efficacy, safety and tolerability of
escitalopram in doses up to 50 mg in MDD. It was conducted in 60 primary care patients with MDD who had not
responded to adequate treatment with citalopram. Patients were treated with escalating doses of escitalopram up
to 50 mg for up to 32 weeks until they achieved remission (Montgomery-Asberg Depression Rating Scale [MADRS]
≤8) or failed to tolerate the dose.
Results: Forty-two patients (70%) completed the study. Twenty-one patients (35%) achieved remission with 8 of
the 21 patients (38%) needing the 50 mg dose to achieve remission. Median time to remission was 24 weeks and
median dose in remission was 30 mg. No significant safety issues were identified although tolerability appeared to
decline above a dose of 40 mg with 26% of patients unable to tolerate 50 mg. Twelve (20%) patients had adverse
events leading to discontinuation. The most common adverse events were headache (35%), nausea, diarrhoea and
nasopharyngitis (all 25%). Minor mean weight gain was found during the study, which did not appear to be dose-
related. Half of the patients who completed the study chose to continue treatment with escitalopram rather than
taper down the dose at 32 weeks.
Conclusions: Dose escalation with escitalopram above 20 mg may have a useful role in the management of
patients with MDD, although further studies are needed to confirm this finding.
Trial Registration: ClinicalTrials.gov: NCT00785434
Background
Selective serotonin reuptake inhibitors (SSRIs) are con-
sidered a first-line pharmacological treatment for major
depressive disorder (MDD). However, up to 50% of
patients may fail to respond to the initial treatment and
as few as 30% achieve the treatment goal of full remission
[1]. Remission has been defined at different levels of the
MADRS scale, but for the purposes of this study we used
the value of <9 as representing relative “wellness” [2].
Three major strategies are recommended by the guide-
lines to manage these patients: dose escalation, augmen-
tation and switching to another antidepressant of the
same or a different class. Dose escalation is often the first
choice of clinicians, although there is limited evidence to
support this strategy.
Citalopram is one of the most commonly used antide-
pressants in the United Kingdom and was selected for
study to standardise and simplify recruitment to the
study. However, citalopram is a racemic mixture of the
R- and S-enantiomers in a 1:1 ratio, with only the S-
enantiomer (escitalopram) associated with antidepressant
activity. It is thought that the R-enantiomer competes
with the S-enantiomer at a low-affinity site on the seroto-
nin reuptake transporters (SERTs), leading to decreased
binding of the S-enantiomer at the high-affinity site [3].
Therefore, increasing the dose of citalopram may not
* Correspondence: alangwade@fastmail.fm
1CPS Research, Glasgow, G20 0XA, UK
Full list of author information is available at the end of the article
Wade et al. BMC Psychiatry 2011, 11:42
http://www.biomedcentral.com/1471-244X/11/42
© 2011 Wade et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
lead to better efficacy of the S-enantiomer due to increas-
ing interference from the R-enantiomer [4].
Escitalopram, uniquely among the SSRIs, potentiates its
own binding, raising the possibility of increasing effect
with increasing doses [5]. In the United Kingdom, it is
currently licensed for the treatment of major depressive
episodes at doses of 5 mg, 10 mg and 20 mg [6]. There is
evidence from marketing data and anecdotal reports that
clinicians are using escitalopram at doses considerably
higher than the recommended maximum of 20 mg. How-
ever, there is little published literature available to sup-
port the use of escitalopram at these higher doses and
none in the treatment of MDD [7].
The relationship between SSRI starting dose and treat-
ment outcome in MDD has been examined recently in a
meta-analysis [8]. This indicated that patients receiving
the usual starting dose of SSRIs (such as 10 mg escitalo-
pram) were less likely to respond than patients who
received higher starting doses. However, starting treat-
ment with higher doses of SSRIs was associated higher
rates of discontinuation due to intolerance.
The objectives of this open-label, pilot study were to
investigate the efficacy, safety and tolerability of escitalo-
pram in doses up to 50 mg in the treatment of MDD.
Methods
Study design
This was an open, pilot study of escitalopram in patients
with MDD who had not responded to treatment with cita-
lopram (clinicaltrials.gov identifier: NCT00785434).
Patients meeting the entry criteria for the study were
recruited by the General Practitioner (GP) and thereafter
managed in conjunction with a CPS research assistant.
Regardless of citalopram dose, patients were switched
abruptly to escitalopram 10 mg and treated with 2-weekly
escalating doses of escitalopram up to a maximum of
50 mg for up to 32 weeks (Table 1) until they either
achieved remission according to the Montgomery-Asberg
Depression Rating Scale [9] (MADRS ≤8) or failed to tol-
erate the dose. Thereafter, patients who achieved remis-
sion were maintained on the remission dosage and
reviewed at 4 weekly intervals. At any subsequent visit
where the MADRS score was >8, the dosage was
increased. Patients unable to tolerate a dose had their
dosage reduced to the previous tolerable dose.
Efficacy, safety and tolerability were assessed at 12
clinic visits over the 34-week study: a baseline visit at day
1, visits at weeks 1, 2, 4, 6, 8 and every 4 weeks until 32
weeks and a follow-up visit 2 weeks after starting taper-
ing down at 32 weeks or at discontinuation. There was
also a safety follow-up 28 days after the 32-week visit,
which was generally performed over the telephone.
Patients were advised to taper down the doses (50 mg
to 40 mg, 40/45 mg to 30 mg, 30/35 mg to 20 mg and
20/25 mg to 10 mg) at the 32-week or discontinuation
visit and then to lower the dose by 10 mg every 3 days
until they stopped taking escitalopram. After this,
patients were managed at the discretion of their supervis-
ing physician.
The investigation was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice
guidelines although a non-conformance in the medica-
tion packaging was recorded which independent review
indicated had no influence on the study results.
Patient population
The study was conducted using a network of GPs based
in central and west Scotland. Patients aged 18-65 years
old diagnosed by the GP with MDD as defined by DSM
IV criteria [10], who had shown an inadequate response
to a primary course of citalopram 20 mg or greater for a
minimum of 6 weeks were eligible for this study. An
inadequate response was defined as failure to achieve a
MADRS score of ≤12. Exclusion criteria included signifi-
cant other psychiatric disorders that would interfere with
trial assessments (co-morbid generalized anxiety disorder
Table 1 Dose schedule
Visit weeks MADRS score Dose of escitaloprama
Week 1 Any 10 mg
Week 2 Any 20 mg
Week 4 Any 20 mg (review visit)
Week 6 <12 Maintain dose at 20 mg
≥12 Increase dose to 30 mg
Week 8 ≤8 Maintain current dose (20 or 30 mg) for 4 weeks
>8 Increase dose (20 mg to 30 mg or 30 mg to 35 mg) for 2 weeksb
4-weekly intervals until Week 32 ≤8 Maintain current dose for 4 weeks
>8 Increase dose (20 mg to 30 mg or 5 mg increment at 2-weekly intervals) up to 50 mgb
a Irrespective of their MADRS score, patients unable to tolerate a higher dose had their dose decreased (30 to 20 mg or 5 mg decrease). Patients with a MADRS
score >8 who were intolerant of a higher dose were maintained on their current dose for 2 or 4 weeks, depending on their visit schedule.
bPatients with a dose increase were assessed at an additional visit 2 weeks later. At this visit, patients with a MADRS ≤8 had their dose maintained for a further 2
weeks, whereas patients with a MADRS >8 had their dose increased for 2 weeks.
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and panic disorder were allowed if MDD was considered
the primary diagnosis), history of mania or bipolar disor-
der, known contraindication for the use of citalopram or
escitalopram, significant bleeding disorder and promi-
nent suicidal ideation (score >4 in the MADRS item
10 (suicidal thoughts)). Patients with any alcohol or sub-
stance dependence in the past 6 months, major physical
illness, significant ECG, hepatic or renal liver abnormal-
ities, pregnant or breastfeeding women and those using
inadequate contraception were also excluded.
The clinical study protocol was approved by the rele-
vant ethics committees and written informed consent
was obtained from each patient prior to enrolment into
the study.
Outcome measures: Efficacy
The primary endpoint was the number (%) of patients
achieving remission, where remission was defined as a
MADRS total score of ≤8. MADRS remission was cho-
sen as the primary variable as it was generally used to
assess patient outcome in clinical trials of escitalopram.
Secondary outcome measures included the number
(%) of patients achieving absolute sustained remission
(reaching a MADRS score of ≤8 and staying at ≤8), sus-
tained remission (reaching a MADRS score of ≤8 and
staying at ≤12) and response (achieving a 50% decrease
in MADRS from baseline MADRS score), mean changes
in the MADRS scores from baseline and changes in
Clinical Global Impressions - Improvement of Illness
(CGI-I) scale [11].
Outcome measures: Safety and tolerability
Safety and tolerability outcomes were assessed from
adverse events (AEs), vital signs, weight, physical exami-
nation and ECG findings, concomitant medication, full
blood count, liver function tests and electrolytes. A Dis-
continuation Emergent Signs and Symptoms (DESS)
scale was used at the 32 week or discontinuation visit
and at a follow up visit 2 weeks later to assess withdra-
wal symptoms [12].
Statistical methods
The primary endpoint for the study was the proportion
of patients enrolled who achieved remission at the end of
the study. In order that this proportion could be esti-
mated to within approximately ±10% (based on an
approximate two sided, 90% confidence interval),
60 patients were enrolled. The 90% confidence level was
used to summarise the primary endpoint for consistency
with the protocol with both sides of the interval pre-
sented for completeness. All other confidence intervals
were presented as two sided, 95% intervals.
Safety and tolerability data were summarised descrip-
tively for the safety population, which included all
patients who took at least one dose of the study drug.
Descriptive analyses for efficacy were performed using
both observed cases (OC) and baseline observation car-
ried forward (BOCF) approaches. Efficacy outcome vari-
ables were summarised for the ‘completer’ population,
which consisted of all patients in the safety population
who reached the final study visit at 34 weeks and for all
patients completing a visit, where appropriate.
Logistic regression analyses were performed to assess
the relationship between age group, gender and history
of anxiety and the probability of achieving remission at
the end of the study. A repeated measures analysis of
covariance (ANCOVA) was carried out to assess the
effects over time on MADRS score. Chi-squared tests
were carried out to test for association between remis-
sion at the end of the study and achieving a 50% reduc-




Sixty patients were enrolled into the study and took study
medication. Forty-two patients (70%) completed the
study and the main reason for treatment discontinuation
was AEs. Of the 18 patients who did not complete treat-
ment, 6 patients discontinued due to an AE in the first
2 weeks of treatment. However, the rate of discontinua-
tion due to an AE was low for patients continuing on
medication after this period (Table 2).
Baseline characteristics
Demographic and clinical characteristics are presented
in Table 3. The study population had a mean age of
43.5 years, a mean BMI of 30.8 and an unusually high
proportion (87%) were women. Forty-two (70%) patients
had a previous psychiatric history, with 3 (5%) patients
having anxiety symptoms present at the baseline visit
(latter result not shown).
Protocol deviations
Three patients who discontinued treatment prematurely
had minor protocol deviations (2-time between visits out
of the specified range, 1-patient not prescribed study
medication due to a hospital admission). In addition,
22 patients who completed the study did not taper down
the dose of escitalopram after the week 32 visit, but
opted to continue taking the medication.
Efficacy
MADRS remission
The number (%) of patients in remission at each study
visit is shown in Figure 1 (all patients, OC). Twenty-one
(35%, 90% CI 25% to 45%) of the 60 patients enrolled
completed the 34-week study and achieved remission by
the end of the study. This represents 50% (90% CI 37%
to 63%) of the 42 patients who completed the study.
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One further patient achieved remission at week 6 but
then discontinued due to an AE (lethargy).
Of the 21 patients who completed the study and
achieved remission, 14 (67%) achieved sustained remis-
sion (achieving a score of ≤8 and staying at ≤12) and
12 (57%) achieved absolute sustained remission (achiev-
ing a score of ≤8 and staying at ≤8). The patients
achieved remission over the range of 20 to 50 mg doses,
with 8 (38%) of the patients requiring the 50 mg dose to
reach this status (Table 4). The median time to remis-
sion was 24 weeks (range 4-34 weeks). At remission, 19
(90.5%) patients were ‘very much improved’ and 2
(9.5%) were ‘much improved’ according to the CGI-I
scale.
Characteristics of patients by remission status
The remission status of patients completing the study is
shown in Table 5 by gender, history of anxiety and age
group. Logistic regression analyses indicated that
women, older patients (≥45 years) and patients with no
history of anxiety may be associated with a higher prob-
ability of achieving remission, but none of these associa-
tions reached statistical significance (Table 5). For
example, the odds of achieving remission were approxi-
mately 4 times higher in those who had not previously
experienced anxiety than those who had (odds ratio
4.10, 95% CI 0.89 to 18.89, p = 0.095).
MADRS Mean Score and Response
The mean MADRS scores over time, estimated using an
ANCOVA model, are shown in Figure 2 for all patients
completing the study (n = 42).
Table 2 Timing and dose at treatment discontinuation
Dose of escitalopram Week of last completed visit Number of patients discontinued
Due to an AEa Not due to an AEa
10 mg Week 0 (baseline) 6 0
Week 8 1 0
20 mg Week 4 1 0
Week 16 1 0
30 mg Week 8 1 0
35 mg Week 8 0 2 (1 - ineligible to continue, 1 - lack of efficacy)
40 mg Week 24 1 0
45 mg Week 24 1 1 (lack of efficacy)
50 mg Week 16 1 0
Week 20 0 1 (lost to follow up)
Week 24 0 1 (lack of efficacy)
a AE: adverse event. The reason for withdrawal was taken from the End of Study Case Report Form (CRF) page. This stated that a patient withdrew due to an AE,
although this was not recorded as a withdrawal as a result of an AE on the AE CRF page.
Table 3 Patient baseline demographic and clinical
characteristics
Characteristic n = 60
Female, n (%) 52 (86.7%)
White, n (%) 60 (100%)
Age, mean (SD), years 43.5 (10.7)
BMI, mean (SD), kg/m2 30.8 (7.9)
Duration of current MDD episode, mean (SD), months a 18.9 (20.2)
Other psychiatric history, n (%) 42 (70.0%)
MADRS score, n (%)
13 - 20 15 (25.0%)
21 - 25 14 (23.3%)
26 - 30 19 (31.7%)
≥31 12 (20.0%)
MADRS score, mean (SD) 25.7 (6.31)
CGI-S score, n (%)
3 - Mildly ill 1 (1.7%)
4 - Moderately ill 32 (53.3%)
5 - Markedly ill 22 (36.7%)
6 - Severely ill 5 (8.3%)
7 - Among the most extremely ill patients 0 (0.0%)
a n = 59.
Figure 1 Percentage of patients in remission per visit, all
patients (observed cases per visit). Visits (Week) 1 (0), 2 (2), 3 (4),
4 (6), 5 (8), 6 (12), 7 (16), 8 (20), 9 (24), 10 (28), 11 (32) and 12 (34).
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MADRS responders (patients with at least a 50%
decrease in MADRS from baseline MADRS score) at
each study visit are shown in Figure 3 (all patients, OC).
A chi-squared test indicated that there was a significant
association between remission at the end of the study
and a 50% reduction in MADRS at 8 weeks when
patients were receiving either 20 or 30 mg of escitalo-
pram (11/14, 78.6% responders in remission, odds ratio
6.60, 95% CI 1.48 to 29.36, p = 0.009).
Safety and tolerability
Escitalopram was generally well tolerated at doses of 10
to 35 mg. Doses of 40 and 50 mg were less well toler-
ated with 26% of patients unable to tolerate the 50 mg
dose (Table 6). However, 8 (38%) of the 21 patients who
achieved remission had received the 50 mg dose.
All 60 patients experienced at least one AE during the
study (Table 7) and a total of 464 AEs were reported.
Table 4 Characteristics of patients in remission (n = 21)
Characteristic
Time to Remission (weeks)
Mean (SD) 21.1 (12.7)
Median 24
Range 4, 34
Time in Absolute Sustained Remission (weeks)a




20 mg, n (%) 5 (23.8)
30 mg, n (%) 2 (9.5)
35 mg, n (%) 4 (19.0)
40 mg, n (%) 2 (9.5)
50 mg, n (%) 8 (38.1)
Dose at the 32-week visit (prior to tapering)
20 mg, n (%) 5 (23.8)
30 mg, n (%) 3 (14.3)
35 mg, n (%) 4 (19.0)
40 mg, n (%) 1 (4.8)
50 mg, n (%) 8 (38.1)
Dose whilst in remission, mgc
Mean (SD) 30.7 (11.0)
Median 30
Range 10, 50
aDose at remission is taken as the dose at first achieving absolute sustained
remission for patients achieving absolute sustained remission, and the dose at
the 32-week visit for those patients not achieving absolute sustained remission.
b Time in absolute sustained remission is taken as the difference between the
34-week visit and the week of first achieving absolute sustained remission for
patients achieving absolute sustained remission, and as 0 weeks for patients
not achieving absolute sustained remission.
c The dose of all episodes of remission i.e. a MADRS score of ≤8.
Table 5 Remission Status by gender, age and history of anxiety and logistic regression analysis to determine the
relationship with probability of remission, completers (n = 42)
Total in remission (MADRS ≤8) Total not in remission (MADRS >8) Odds ratio (95% CI) P-value
N (% of 42) 21 (50) 21 (50)
Gender
Female, n (% of n = 39) 20 (51.3) 19 (48.7)
Male, n (% of n = 3) 1 (33.3) 2 (66.7) 3.33 (0.24-45.76) 0.350
History of anxiety
No, n (% of n = 13) 9 (69.2) 4 (30.8)
Yes, n (% of n = 29) 12 (41.4) 17 (58.6) 4.10 (0.89-18.89) 0.095
Age group
Aged <45, n (% of n = 22) 9 (40.9) 13 (59.1)
Aged ≥45, n (% of n = 20) 12 (60.0) 8 (40.0) 0.44 (0.12-1.63) 0.189
Odds ratios for female vs. male, aged <45 vs. ≥45, no history of anxiety vs. no history of anxiety from logistic regression analysis.
Figure 2 MADRS scores over time, completers (n = 42). The fitted
mean and 95% confidence intervals were estimated using a repeated
measures analysis of covariance (ANCOVA). The fitted model included
terms for time, gender age group and history of anxiety as factors,
with the baseline Montgomery-Asberg Depression Rating Scale
(MADRS) score and baseline body mass index (BMI) fitted as covariates.
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Twelve (20%) patients discontinued due to an AE; 7
patients discontinued on the 10 mg dose, 2 patients on
the 20 mg dose and 3 patients on doses of 30 to 50 mg.
Two patients experienced a serious AE (1-mild cataract,
1-severe ankle fracture), but these were not assessed as
treatment-related by the investigators. The most com-
mon treatment-emergent AEs are presented in Table 8.
At the 50 mg dose, the AE with the highest incidence
was diarrhoea (5/31, 16%).
There was an increase of 0.83 kg (SD 4.86, n = 56) from
baseline to the final visit in weight and 3.75 bpm (SD
10.90, n = 57) in the heart rate (safety population). Four
(6.7%) patients reported weight gain as an AE and one
patient discontinued treatment due to weight gain. The
percentage weight gain is presented by dose at final visit
for patients completing the study in Figure 4 and shows
that weight gain did not appear to be dose related.
Potentially clinically significant weight gain (>7%) was
found in 12% of patients completing the study (though
note that significant weight loss (>7%) was found in 10%
of the same group).
Two patients had potentially clinically significant
changes during the study. One patient, a 22 year-old
female, with a normal ECG at baseline had an abnormal
ECG (inverted T wave) at the end of the study, although
this was assessed as not clinically significant by an inde-
pendent assessor. Another female patient had a clinically
significant blood test (raised g-glutamyl transferase
[GGT] 175 IU/L) at the end of the study, which was
within the normal range at baseline (25 IU/L). After com-
pleting the study, the patient remained on escitalopram
on the decision of her supervising clinician. Regular fol-
low up assessments have shown that her GGT level is
starting to revert towards normal.
Twenty of the 42 (48%) patients completed the study
and tapered down the dose of escitalopram at 32 weeks
prior to stopping treatment as given in the protocol.
Twelve of these patients (60%) reported either no new
symptoms or one new symptom on discontinuation, as
assessed using the DESS scale scores (Figure 5). The most
Figure 3 Percentage of patients responding per visit, all patients
(observed cases per visit). Response was defined as a 50% decrease
in MADRS from baseline MADRS score. Visits (Week) 1 (0), 2 (2), 3 (4), 4
(6), 5 (8), 6 (12), 7 (16), 8 (20), 9 (24), 10 (28), 11 (32) and 12 (34).
Table 6 Number (%) of patients intolerant of each dose, safety population (n = 60)
Dose
(mg)
Number of patients on this dose at any time, with data available on
tolerabilitya
Number (% of n) of patients intolerant of this dose at
any time
10 55 1 (1.8)
20 54 3 (5.6)
30 47 2 (4.3)
35 41 3 (7.3)
40 34 1 (2.9)
45 32 4 (12.5)
50 31 8 (25.8)
a Reduced numbers are as a result of patient withdrawals. Additionally, some patients titrated more slowly up the doses or never reached the higher doses.
Table 7 Number (%) of patients reporting an adverse
event, safety population
Category of AE n = 60
Any adverse events (AEs) 60 (100)
Treatment-related AEs
Possibly treatment-related 32 (53.3)
Probably treatment-related 16 (26.7)
Definitely treatment-related 0 (0)
Serious AEs 2 (3.3)
Serious treatment-related AEs a 0 (0)
Discontinuations due to AEs b 12 (20.0)
Treatment-related discontinuations due to AE a 10 (16.7)
aNumber (%) of patients with an AE assessed as possibly, probably or
definitely related to study medication.
bThe AE case report form (CRF) page captured information regarding whether
a patient withdrew from the study as a result of an AE. The End of Study CRF
page captured withdrawal information and stated that a patient withdrew
due to an AE, although this was not recorded as a withdrawal as a result of
an AE on the AE CRF page.
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common new symptoms (≥15%) on stopping escitalopram
were headache, dizziness, light-headedness or vertigo and
muscle tension or stiffness.
Discussion
This study showed that approximately one third of the
patients who had not responded to treatment with at
least 20 mg of citalopram for at least 6 weeks achieved
remission (MADRS ≤8) during the 34 weeks of treat-
ment with doses of escitalopram at doses up to 50 mg.
A further third did not complete the study for a range
of reasons including intolerance of escitalopram. Thus,
Table 8 Most common adverse events (reported by ≥10% of patients), total and by dose at onset of AE, safety
population (n = 60)
Number (%) of patients
Dose at onset
Preferred term Total 10 mg 20 mg 30, 35 mg 40, 45 mg 50 mg
Headache 21 (35.0) 10 (16.7) 6 (10.0) 5 (8.3) 1 (1.7) 3 (5.0)
Nausea 15 (25.0) 6 (10.0) 3 (5.0) 3 (5.0) 2 (3.3) 2 (3.3)
Diarrhoea 15 (25.0) 6 (10.0) 3 (5.0) 3 (5.0) 2 (3.3) 5 (8.3)
Nasopharyngitis 15 (25.0) 5 (8.3) 2 (3.3) 6 (10.0) 1 (1.7) 2 (3.3)
Hyperhidrosis 12 (20.0) 3 (5.0) 3 (5.0) 4 (6.7) 1 (1.7) 1 (1.7)
Upper respiratory tract infection 12 (20.0) 2 (3.3) 5 (8.3) 3 (5.0) 2 (3.3) 2 (3.3)
Fatigue 10 (16.7) 3 (5.0) 1 (1.7) 2 (3.3) 5 (8.3) 0 (0)
Dizziness 10 (16.7) 3 (5.0) 2 (3.3) 4 (6.7) 0 (0) 1 (1.7)
Vomiting 8 (13.3) 3 (5.0) 1 (1.7) 4 (6.7) 0 (0) 2 (3.3)
Abnormal dreams 6 (10.0) 2 (3.3) 0 (0) 3 (5.0) 1 (1.7) 1 (1.7)
Arthralgia 6 (10.0) 0 (0) 3 (5.0) 0 (0) 3 (5.0) 0 (0)
Back pain 6 (10.0) 0 (0) 2 (3.3) 2 (3.3) 1 (1.7) 1 (1.7)
Influenza like illness 6 (10.0) 1 (1.7) 1 (1.7) 1 (1.7) 1 (1.7) 3 (5.0)
Influenza 6 (10.0) 0 (0) 2 (3.3) 1 (1.7) 0 (0) 3 (5.0)
Lethargy 6 (10.0) 2 (3.3) 2 (3.3) 0 (0) 2 (3.3) 0 (0)
Oropharyngeal pain 6 (10.0) 0 (0) 2 (3.3) 2 (3.3) 1 (1.7) 1 (1.7)
Pain in extremity 6 (10.0) 0 (0) 2 (3.3) 3 (5.0) 2 (3.3) 0 (0)
Rash 6 (10.0) 2 (3.3) 2 (3.3) 0 (0) 1 (1.7) 2 (3.3)
Figure 4 Percentage weight change from baseline to end of
study, by 32 week dose, completers (n = 42). The box and
whisker plot shows the mean with upper and lower quartiles in the
box and the whisker the minimum and maximum excluding
outliers. Outliers are indicated by the small circles.
Figure 5 Number of Discontinuation Emergent Signs and
Symptoms reported by completers stopping treatment with
escitalopram (n = 20). The number of new symptoms reported by
the 20 patients who completed the study and tapered down the
dose of escitalopram at 32 weeks prior to stopping treatment, as
assessed using the Discontinuation Emergent Signs and Symptoms
(DESS) scale scores.
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half of those who did complete the study achieved
remission.
Entry to the study was based on a minimum treatment
with citalopram for six weeks, but neither dosage regime
nor length of treatment was recorded. This and the dif-
ference in remission criteria make comparisons with
outcomes in other studies such as STAR-D difficult.
The patients could not strictly be described as treatment
resistant and so comparison with the initial phase
patients in STAR-D may be appropriate. In STAR-D, a
remission rate of 28% as assessed by HAM-D ≤7 was
achieved with a mean citalopram dose of 41.8 mg pre-
scribed by physicians for up to 14 weeks. In this study,
40.8% of patients were in remission (MADRS ≤8) at 16
weeks following an accelerated dosage programme at a
mean dose of 41 mg escitalopram.
Factors such as gender, age group and history of anxi-
ety may influence outcome and although none of the
associations were statistically significant in this study,
these should be investigated in further studies.
Patients who responded at 8 weeks were significantly
more likely to achieve remission at the end of the study.
Therefore, a response to 20 or 30 mg at 8 weeks of this
regime may be a useful predictor for achieving MADRS
remission.
Doses up to 40 mg were generally well tolerated by
patients in this study, with doses above this less well tol-
erated. Although 26% of all patients were unable to tol-
erate doses of 45 to 50 mg, 38% of the 21 patients who
achieved remission needed the 50 mg dose.
There were no unexpected safety issues arising from
the use of the higher doses of escitalopram in this study
and only a small weight gain was observed, which did
not appear to be dose related. Further studies are
needed to establish the role of dose escalation of escita-
lopram in the management of patients with MDD who
have not responded to conventional treatment with
escitalopram.
Limitations of the study were the open nature of the
study design, the small number of male patients and the
high mean BMI of the study population (30.8), which
may have influenced weight changes during treatment.
No formal attempt was made to assess compliance dur-
ing the study. The data have also been presented using
OC and BOCF approaches. A last observation carried
forward (LOCF) approach was not used to provide data
for the 18 patients who discontinued the study. The rea-
sons for this were that 6 patients withdrew after the first
visit and had no available efficacy data and 9 patients
had large fluctuations in the patterns of MADRS scores
(results not shown). An LOCF approach could be justi-
fied for the remaining 3 patients who all withdrew after
week 8, based on the MADRS pattern, although 2 of
these withdrew due to AEs and one was ineligible to
continue.
The data obtained from this pilot study might be used
for the design of any subsequent clinical development
programme. In the sample size calculations for this
study, the assumptions of an attrition rate of 10% and a
MADRS remission rate of 70% were not met and should
be revised in any future trials. The observed attrition rate
of 30% was considerably higher than expected, whereas
the remission rate of 50% achieved was lower than
expected. The high drop-out rate was mainly due to
patients discontinuing due to AEs and this was particu-
larly evident in the first two weeks of treatment. Consid-
eration should be given to how the drop-out rate could
be limited in future trials, possibly by improving patient
awareness of the transient nature of some side effects
including worsening of depression/anxiety/low mood on
changing to a low dose of another medication.
Conclusions
Dose escalation with escitalopram above 20 mg may
have a useful role in the management of patients with
treatment-resistant MDD, although larger randomised
controlled studies are needed to confirm this finding.
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